

ASX Announcement

Imugene Adds Industry Leaders Ursula McCurry and Dr Nimali Withana to Senior Management Team

Sydney, Australia, 4 January 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced the appointment of industry leaders Ursula McCurry and Dr Nimali Withana to its senior management team. They are both former Roche/Genentech employees and experts in oncology clinical development, commencing their positions with Imugene on 1 January 2022.

Ursula McCurry is appointed as the Senior Vice President of Clinical Operations. Ursula is a seasoned clinical operations leader with over 20 years of global clinical development experience across a number of established and emerging biotech and pharmaceutical companies including Genentech, Exelixis, Astex, QLT Inc and Amunix. She has led global clinical operations programs spanning a variety of therapeutic areas and all phases of clinical development, contributing to over 20 programs and subsequent multiple regulatory approvals at both small and large biotech companies. She also brings significant partnership and alliance management experience. Prior to joining Imugene, Ursula served as the VP of Clinical Operations at Amunix Pharmaceuticals and prior to that was a Clinical Program Director at Genentech, leading multiple programs from entry into the clinic to phase three development, including taselisib and GDC-9545. She has also led the Drug Safety teams, ensuring quality, compliance, pharmacovigilance, and safety reporting.

Ursula received a Master of Arts degree from Simon Fraser University and a certificate in Biotechnology, Clinical Trial Design and Management from San Francisco State University.

Dr Nimali Withana is appointed Senior Director of Clinical Science and has over 18 years of drug development experience spanning both academia and industry. Most recently she was the Lead Country Medical Manager for the Breast Cancer and Cancer Immunotherapy portfolios including bevacizumab, trastuzumab emtansine, ipatasertib and atezolizumab at Hoffman-La Roche New Zealand. Prior to that, she was the Clinical Scientist Lead across Phase I – III global oncology trials at Genentech.

Dr Withana received her academic training at Stanford University and The Peter MacCallum Cancer Centre, majoring in Immunology and Molecular Medicine. She has an in-depth understanding and grasp of the development process with experience in R&D, Clinical Trials and Patient Advocacy.

Imugene CEO and MD Leslie Chong said: “Ursula and Nimali add critical and considerable clinical development capability to our senior management team, and I am delighted to welcome them to Imugene.”

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
investor@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer
Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia